{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:59:47Z","timestamp":1784714387604,"version":"3.55.0"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Oral icotrokinra, a selective interleukin-23 receptor antagonist, is an emerging treatment for moderate-to-severe plaque psoriasis in adults and adolescents. Clinical trials show it significantly reduces Psoriasis Area and Severity Index (PASI) scores and provides symptom relief. It works well in patients who have not used systemic therapies before or have widespread disease. Unlike injectable treatments, icotrokinra is taken orally, making it more convenient and potentially improving adherence. It has shown an effective safety profile, with mostly mild side effects like stomach discomfort and no serious adverse events. As interest in this therapy grows, it may become an important option in psoriasis care, helping to improve quality of life and reduce the long-term burden of this chronic skin condition.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004427","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:03:27Z","timestamp":1764950607000},"page":"1064-1065","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Oral icotrokinra for plaque psoriasis in adults and adolescents"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7072-6560","authenticated-orcid":false,"given":"Erum","family":"Habib","sequence":"first","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan"},{"name":"Nibras Research Academy, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2356-0751","authenticated-orcid":false,"given":"Ursula Abu","family":"Nahla","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebron University, Hebron, Palestinian Territory, Occupied"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haris","sequence":"additional","affiliation":[{"name":"Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[{"name":"Nibras Research Academy, Lahore, Pakistan"},{"name":"Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"1784\u201395","DOI":"10.1056\/NEJMoa2504187","article-title":"Oral icotrokinra for plaque psoriasis in adults and adolescents","volume":"393","author":"Bissonnette","year":"2025","journal-title":"N Engl J Med"},{"key":"R3-20260514","article-title":"Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20260514","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","author":"Science","year":"2025","journal-title":"Prem J Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:01:30Z","timestamp":1778749290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004427","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2025-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}